Respiratory Diseases Respiratory Diseases We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
New Partnership to Develop Gene Therapy for Cystic Fibrosis New Partnership to Develop Gene Therapy for Cystic Fibrosis Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
Boehringer receives SBTi validation for CO2 reduction targets Boehringer receives SBTi validation for CO2 reduction targets Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
Boehringer partners with NCD Alliance Boehringer partners with NCD Alliance Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
Boehringer Ingelheim Academy Video 2023 Boehringer Ingelheim Academy Video 2023 Boehringer Ingelheim’s Academy initiative provides networking opportunities, education and facilitates conversations across the innovation community.
Boehringer unveils first global sustainability publication Boehringer unveils first global sustainability publication Boehringer Ingelheim unveils its first global sustainability publication ‘Imagine’
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
Accelerating new cancer medicines in partnership with CBmed Accelerating new cancer medicines in partnership with CBmed Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
collaboration criving innovation collaboration criving innovation In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Boehringer acquires T3 Pharma Boehringer acquires T3 Pharma Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Welcome to Innovation at Boehringer Ingelheim Welcome to Innovation at Boehringer Ingelheim Watch our video and find out more about innovation at Boehringer Ingelheim.
Boehringer Ingelheim good 2021 business performance Boehringer Ingelheim good 2021 business performance 2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
Partnering with Lifebit to detect global disease outbreaks Partnering with Lifebit to detect global disease outbreaks Boehringer Ingelheim partners with Lifebit to detect global infectious disease outbreaks
Animal Health partnering interests Animal Health partnering interests Animal Health partnering interests
Award: Boehringer Ingelheim is Global Top Employer 2022 Award: Boehringer Ingelheim is Global Top Employer 2022 Global Top Employer 2022
Boehringer Ingelheim announces appointments Boehringer Ingelheim announces appointments Boehringer Ingelheim announces appointments
Partnership to Develop Urea Cycle Disorders Therapy Partnership to Develop Urea Cycle Disorders Therapy Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Boehringer Ingelheim reaches more patients than ever, innovation drives growth Boehringer Ingelheim reaches more patients than ever, innovation drives growth Boehringer Ingelheim reports a strong performance in 2022.
Boehringer Ingelheim appointment to Board Managing Directors Boehringer Ingelheim appointment to Board Managing Directors Boehringer Ingelheim announces appointments to Board of Managing Directors
Immunology Immunology We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
Meet the BD&L Team 2019 Meet the BD&L Team 2019 Hear from our team and find out more about our approach to partnering.
Flood-disaster-in-Germany-donation-from-Boehringer-Ingelheim Flood-disaster-in-Germany-donation-from-Boehringer-Ingelheim Boehringer Ingelheim increases donation for emergency flood relief to EUR 1 million
Boehringer Ingelheim strong growth pipeline acceleration 2023 Boehringer Ingelheim strong growth pipeline acceleration 2023 Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim 2022 half year results Boehringer Ingelheim 2022 half year results First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline